CU20130135A7 - Imidazopiridazinas como inhibidores de quinasa akt - Google Patents

Imidazopiridazinas como inhibidores de quinasa akt

Info

Publication number
CU20130135A7
CU20130135A7 CU2013000135A CU20130135A CU20130135A7 CU 20130135 A7 CU20130135 A7 CU 20130135A7 CU 2013000135 A CU2013000135 A CU 2013000135A CU 20130135 A CU20130135 A CU 20130135A CU 20130135 A7 CU20130135 A7 CU 20130135A7
Authority
CU
Cuba
Prior art keywords
imidazopiridazinas
quinasa
akt inhibitors
akt
inhibitors
Prior art date
Application number
CU2013000135A
Other languages
English (en)
Other versions
CU24263B1 (es
Inventor
Lars Bärfacker
William Johnston Scott
Andrea Hägebarth
Stuart Ince
Hartmut Rehwinkel
Oliver Politz
Roland Neuhaus
Hans Briem
Ulf Bömer
Original Assignee
Bayer Pharma AG
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG, Bayer Ip Gmbh filed Critical Bayer Pharma AG
Publication of CU20130135A7 publication Critical patent/CU20130135A7/es
Publication of CU24263B1 publication Critical patent/CU24263B1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/5025Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Cosmetics (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Imidazopiridazinas de fórmula (I) un proceso para su producción y el uso de las mismas.
CUP2013000135A 2011-04-07 2012-04-05 Derivados de imidazopiridazinas inhibidores de quinasa akt, útiles para el tratamiento del cáncer CU24263B1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161472732P 2011-04-07 2011-04-07
PCT/EP2012/056300 WO2012136776A1 (en) 2011-04-07 2012-04-05 Imidazopyridazines as akt kinase inhibitors

Publications (2)

Publication Number Publication Date
CU20130135A7 true CU20130135A7 (es) 2014-02-28
CU24263B1 CU24263B1 (es) 2017-07-04

Family

ID=45953129

Family Applications (1)

Application Number Title Priority Date Filing Date
CUP2013000135A CU24263B1 (es) 2011-04-07 2012-04-05 Derivados de imidazopiridazinas inhibidores de quinasa akt, útiles para el tratamiento del cáncer

Country Status (42)

Country Link
US (2) US9206185B2 (es)
EP (1) EP2694510B1 (es)
JP (1) JP5906303B2 (es)
KR (1) KR20140022057A (es)
CN (1) CN103596957B (es)
AP (1) AP3597A (es)
AR (1) AR087148A1 (es)
AU (1) AU2012238589B2 (es)
BR (1) BR112013025777A2 (es)
CA (1) CA2832374A1 (es)
CL (1) CL2013002878A1 (es)
CO (1) CO6862145A2 (es)
CR (1) CR20130515A (es)
CU (1) CU24263B1 (es)
CY (1) CY1117163T1 (es)
DK (1) DK2694510T3 (es)
DO (1) DOP2013000226A (es)
EA (1) EA024890B1 (es)
EC (1) ECSP13013008A (es)
ES (1) ES2558780T3 (es)
GT (1) GT201300238A (es)
HR (1) HRP20160011T1 (es)
HU (1) HUE026323T2 (es)
IL (1) IL228567A0 (es)
JO (1) JO3068B1 (es)
MA (1) MA35016B1 (es)
ME (1) ME02316B (es)
MX (1) MX336865B (es)
NI (1) NI201300105A (es)
PE (1) PE20141380A1 (es)
PL (1) PL2694510T3 (es)
PT (1) PT2694510E (es)
RS (1) RS54480B1 (es)
SG (1) SG193631A1 (es)
SI (1) SI2694510T1 (es)
SM (1) SMT201600001B (es)
TN (1) TN2013000400A1 (es)
TW (1) TWI535719B (es)
UA (1) UA111739C2 (es)
UY (1) UY34006A (es)
WO (1) WO2012136776A1 (es)
ZA (1) ZA201307223B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9447049B2 (en) 2010-03-01 2016-09-20 University Of Tennessee Research Foundation Compounds for treatment of cancer
EP3289876B1 (en) 2008-06-16 2022-07-20 University of Tennessee Research Foundation Compounds for treatment of cancer
US9029408B2 (en) 2008-06-16 2015-05-12 Gtx, Inc. Compounds for treatment of cancer
US11084811B2 (en) 2010-03-01 2021-08-10 Oncternal Therapeutics, Inc. Compounds for treatment of cancer
RU2581367C2 (ru) 2010-03-01 2016-04-20 Джи Ти Икс, ИНК. Соединения для лечения рака
HUE026323T2 (en) * 2011-04-07 2016-05-30 Bayer Ip Gmbh Imidazopyridazines as AKT kinase inhibitors
JP6088542B2 (ja) * 2012-01-10 2017-03-01 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH Aktキナーゼ阻害剤としての置換イミダゾピラジン類
ES2589955T3 (es) * 2012-01-10 2016-11-17 Bayer Intellectual Property Gmbh Pirazolopirimidinas sustituidas como inhibidores de la quinasa Akt
IL266415B2 (en) * 2012-11-30 2024-03-01 Glaxosmithkline Llc Innovative pharmaceutical composition
KR102246652B1 (ko) * 2013-03-05 2021-04-29 유니버시티 오브 테네시 리서치 파운데이션 암 치료용 화합물
WO2014158467A1 (en) * 2013-03-12 2014-10-02 Glaxosmithkline Llc Combination
US20160045531A1 (en) * 2013-03-14 2016-02-18 Epizyme, Inc. Combination therapy for treating cancer
US10214545B2 (en) * 2014-01-09 2019-02-26 Bayer Pharma Aktiengesellschaft Amido-substituted imidazopyridazines useful in the treatment of hyper-proliferative and/or angiogenesis disorders
EP3544980B1 (en) * 2016-11-28 2021-10-13 Bristol-Myers Squibb Company Gsk-3 inhibitors
EP3453706A1 (en) 2017-09-08 2019-03-13 Basf Se Pesticidal imidazole compounds

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6649629B2 (en) 1999-12-23 2003-11-18 Nitromed, Inc. Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use
WO2001074815A2 (en) 2000-03-31 2001-10-11 Ortho Mcneil Pharmaceutical, Inc. Phenyl-substituted imidazopyridines
AU2001252609A1 (en) 2000-04-27 2001-11-12 Imperial Cancer Research Technology Ltd. Imidazopyridine derivatives
JP2006520796A (ja) 2003-03-17 2006-09-14 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼインヒビター
JP4616831B2 (ja) 2003-04-24 2011-01-19 メルク・シャープ・エンド・ドーム・コーポレイション Akt活性の阻害剤
CA2534292A1 (en) 2003-07-30 2005-02-17 Laboratorios S.A.L.V.A.T., S.A. Substituted imidazopyrimidines for the prevention and treatment of cancer
JP2007532558A (ja) 2004-04-09 2007-11-15 メルク エンド カムパニー インコーポレーテッド Akt活性の阻害剤
JP2008510823A (ja) 2004-08-23 2008-04-10 メルク エンド カムパニー インコーポレーテッド Akt活性阻害剤
CN101006062A (zh) 2004-08-24 2007-07-25 巴斯福股份公司 用作生产离子液体的起始化合物的咪唑甲基亚硫酸盐
EP1827436A4 (en) 2004-12-15 2011-08-10 Merck Sharp & Dohme ACTIVITY INHIBITORS AKT
AU2006247118A1 (en) 2005-05-20 2006-11-23 Array Biopharma Inc. Raf inhibitor compounds and methods of use thereof
CA2610888C (en) 2005-06-10 2011-02-08 Merck & Co., Inc. Inhibitors of akt activity
US20070049591A1 (en) 2005-08-25 2007-03-01 Kalypsys, Inc. Inhibitors of MAPK/Erk Kinase
PE20070978A1 (es) 2006-02-14 2007-11-15 Novartis Ag COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks)
US7530313B2 (en) 2006-05-12 2009-05-12 Day & Zimmerman, Inc. Self-destruct fuze delay mechanism
AR064010A1 (es) 2006-12-06 2009-03-04 Merck & Co Inc Inhibidores de la actividad de la akt
MX2009013213A (es) * 2007-06-08 2010-03-30 Abbott Lab Indazoles 5-sustituidos 5-heteroarilo como inhibidores de cinasa.
EP2188291B1 (en) 2007-08-14 2012-09-19 Bayer Pharma Aktiengesellschaft Fused bicyclic pyrimidines
EP2176259B1 (en) * 2007-08-14 2011-03-30 Bayer Schering Pharma Aktiengesellschaft Fused imidazoles for cancer treatment
CA2710458A1 (en) 2007-12-21 2009-07-09 Wyeth Llc Imidazo [1,2-b] pyridazine compounds as modulators of liver x receptors
EP2303269B1 (en) 2008-06-03 2014-07-30 Merck Sharp & Dohme Corp. Inhibitors of akt activity
MX2010013224A (es) 2008-06-03 2010-12-21 Merck Sharp & Dohme Inhibidores de la actividad de la serina/treonina cinasa.
AR074072A1 (es) 2008-11-11 2010-12-22 Lilly Co Eli Compuesto de imidazol -piperidin -pirrol-pirimidin-6-ona, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para tratar el glioblastoma multiforme
PA8854101A1 (es) 2008-12-18 2010-07-27 Ortho Mcneil Janssen Pharm Derivados de imidazol bicíclicos sustituidos como moduladores de gamma secretasa
CA2750051A1 (en) 2009-02-02 2010-08-05 Merck Sharp & Dohme Corp. Inhibitors of akt activity
WO2010091808A1 (en) * 2009-02-13 2010-08-19 Bayer Schering Pharma Aktiengesellschaft Fused pyrimidines
EP2406250B1 (en) 2009-03-11 2015-08-12 Merck Sharp & Dohme Corp. Inhibitors of akt activity
EP2413932A4 (en) 2009-04-01 2012-09-19 Merck Sharp & Dohme INHIBITORS OF AKT ACTIVITY
AR076936A1 (es) 2009-06-02 2011-07-20 Vitae Pharmaceuticals Inc Inhibidores de carbamato y urea de la 11 beta hidroxiesteroide deshidrogenasa 1
WO2011033265A1 (en) 2009-09-18 2011-03-24 Almac Discovery Limited Pharmaceutical compounds
WO2012007345A2 (en) * 2010-07-12 2012-01-19 Bayer Pharma Aktiengesellschaft Substituted imidazo[1,2-a]pyrimidines and -pyridines
CN103384670B (zh) * 2010-07-28 2016-05-25 拜耳知识产权有限责任公司 取代的咪唑并[1,2-b]哒嗪
HUE026323T2 (en) * 2011-04-07 2016-05-30 Bayer Ip Gmbh Imidazopyridazines as AKT kinase inhibitors

Also Published As

Publication number Publication date
CN103596957A (zh) 2014-02-19
NI201300105A (es) 2014-07-14
AP2013007215A0 (en) 2013-10-31
CR20130515A (es) 2013-12-04
SG193631A1 (en) 2013-11-29
MA35016B1 (fr) 2014-04-03
CO6862145A2 (es) 2014-02-10
MX336865B (es) 2016-02-04
PL2694510T3 (pl) 2016-03-31
CN103596957B (zh) 2016-12-07
AR087148A1 (es) 2014-02-26
MX2013011699A (es) 2014-01-31
ECSP13013008A (es) 2013-12-31
EA024890B1 (ru) 2016-10-31
HRP20160011T1 (hr) 2016-02-12
KR20140022057A (ko) 2014-02-21
CY1117163T1 (el) 2017-04-05
EP2694510B1 (en) 2015-10-14
BR112013025777A2 (pt) 2016-12-20
TW201245204A (en) 2012-11-16
UA111739C2 (uk) 2016-06-10
US20150368250A1 (en) 2015-12-24
ES2558780T3 (es) 2016-02-08
ZA201307223B (en) 2014-12-23
EA201301130A1 (ru) 2014-07-30
JP5906303B2 (ja) 2016-04-20
GT201300238A (es) 2015-04-06
NZ616270A (en) 2015-09-25
US20140113901A1 (en) 2014-04-24
IL228567A0 (en) 2013-12-31
PT2694510E (pt) 2016-02-08
TWI535719B (zh) 2016-06-01
ME02316B (me) 2016-06-20
DK2694510T3 (en) 2016-01-18
EP2694510A1 (en) 2014-02-12
JO3068B1 (ar) 2017-03-15
SI2694510T1 (sl) 2016-02-29
CA2832374A1 (en) 2012-10-11
AP3597A (en) 2016-02-19
HUE026323T2 (en) 2016-05-30
UY34006A (es) 2012-10-31
AU2012238589B2 (en) 2017-02-16
CU24263B1 (es) 2017-07-04
JP2014510127A (ja) 2014-04-24
PE20141380A1 (es) 2014-10-18
AU2012238589A1 (en) 2013-11-07
US9206185B2 (en) 2015-12-08
CL2013002878A1 (es) 2014-05-02
SMT201600001B (it) 2016-02-25
TN2013000400A1 (en) 2015-03-30
RS54480B1 (en) 2016-06-30
US9604989B2 (en) 2017-03-28
WO2012136776A1 (en) 2012-10-11
DOP2013000226A (es) 2013-11-15

Similar Documents

Publication Publication Date Title
CU20130135A7 (es) Imidazopiridazinas como inhibidores de quinasa akt
UY34092A (es) Nuevos compuestos como inhibidores de jak
SV2017005487A (es) Derivados de 4h-pirrol[3,2-c]piridin-4-ona
DOP2014000062A (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
UY34051A (es) Derivados de pirrolotriazinona como inhibidores de pi3k
CR20140166A (es) Compuestos de (hetero)arilciclopropilamina como inhibidores de lsd1
UY33929A (es) Compuestos de ciclohexilo tetrasustituido como inhibidores de quinasas
UY33925A (es) Inhibidores tricíclicos de quinasas
UY34045A (es) Derivados de imidazopiridina como inhibidores de pi3k
UY34648A (es) Amidas como inhibidores de pim
UY35467A (es) Compuestos orgánicos
UY33930A (es) Inhibidores novedosos de quinasas
UY33958A (es) Inhibidores de la glucosilceramida sintasa
UY34401A (es) Métodos para el tratamiento de hcv
ECSP13012958A (es) Inhibidores de benzodioxano de la producción de leucotrieno.
UY34212A (es) Derivados de piridin-2(1h)-ona como inhibidores de jak
UY34402A (es) Métodos para el tratamiento de hcv
CL2012000590A1 (es) Proceso para preparar w-transaminasa (r)-selectiva.
UY34108A (es) ?proceso para la fabricación de sustratos revestidos?.
UY33888A (es) Derivados de (1,2,4) triazolo [4,3-a) quinoxalina como inhibidores de fosfodiesterasas
BR112013029015A2 (pt) métodos para controlar a despolimerização de composições poliméricas
CR20130597A (es) Isoxazolinas como agentes terapèuticos
BR112013023253A2 (pt) método para fabricação de um artigo absorvente
UY33926A (es) Método y disposición para calcinar lodos de cal
UY34001A (es) Agentes para el control de la avispa de las agallas